ArticleFASEB bioAdvances2026
Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications.
Article in FASEB bioAdvances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor primarily used to treat type 2 diabetes by lowering blood glucose levels. In addition to its antidiabetic action, it has demonstrated cardioprotective and renoprotective effects, along with antioxidant, anti-inflammatory, and anticancer activities. Encapsulation of dapagliflozin in nanocarriers represents an innovative strategy to improve existing therapies and develop targeted treatments. Such formulations can enhance solubility and stability, improve epithelial permeability and bioavailability, and reduce potential side effects. This study investigates the cellular and molecular effects of dapagliflozin encapsulated in chitosan nanoparticles, focusing on colon (Caco-2) cells. The findings showed that free dapagliflozin significantly reduced cell viability, whereas the encapsulated form preserved high cell viability. In addition, the encapsulated drug effectively reduced reactive oxygen species levels, maintaining its antioxidant activity. Free dapagliflozin did not increase the expression of Nrf2, NFκB, or HO-1 signaling pathways. In contrast, encapsulation in chitosan nanoparticles resulted in increased expression of all three pathways, indicating potential regulatory involvement in these signaling mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.